Towards a harmonisation of EU member state stem cell law
This article was originally published in Clinica
Executive Summary
The disparate legislative approaches of EU member states with regard to stem cell research could soon be en route to convergence, thanks to Germany’s highest court. The Bundesgerichtshof (federal supreme court) has recently referred to the European Court of Justice a case in which the environmental organisation, Greenpeace, challenged a patent granted by the European Patent Office to Oliver Brüstle. The patent concerned a process for producing neuronal or glial progenitor cells. Greenpeace maintained that these would have to be obtained from embryos.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.